logo conference-reports

Conference Reports

An educational program funded by logo MSD Oncology

BLOOD 2019 – Disease burden analysis of HRQoL of blinatumomab versus standard-of-care chemotherapy in patients with R/R Ph– B-ALL in the TOWER study

HRQoL measures stabilised in R/R Ph– B-cell ALL patients treated with blinatumomab whereas declined rapidly in patients receiving chemotherapy